Cardica MicroCutter® XCHANGE 30 Featured At Society Of American
Gastrointestinal And Endoscopic Surgeons Meeting
REDWOOD CITY, Calif., April 24, 2014
REDWOOD CITY, Calif., April 24, 2014 /PRNewswire/ --Cardica, Inc. (Nasdaq:
CRDC) today announced that Radu Pescarus, M.D., Foregut Fellow in the
Gastrointestinal and Minimally Invasive Surgery Division of Providence
Portland Medical Center, presented a poster detailing the pre-clinical use of
the MicroCutter^® XCHANGE 30 surgical stapling device in cutting-edge
gastrointestinal surgical procedures including endoscopic assisted
trans-gastric and trans-anal full thickness resections.
"With its slim profile, secure closure and large range of articulation, the
MicroCutter XCHANGE 30 stapling device has the potential to alleviate some of
the ongoing challenges in performing less invasive endoscopic procedures,"
commented Dr. Pescarus. "This device can be easily incorporated into
laparoscopic or endoscopic procedures, where currently available commercial
laparoscopic staplers have not been suitable for these procedures due to their
bulk, making them impractical to manipulate in the gastric or colonic lumen.
Importantly, the precise and secure closure obtained with the MicroCutter may
avoid peritoneal seeding and contamination, both large concerns when a
malignant tumor is present at the surgical site, providing better patient
Dr. Pescarus' poster, entitled 'Endoscopic assisted trans-gastric and
colorectal full thickness resections are enabled by a novel 5 mm surgical
stapler,' were presented on earlier this month during the Emerging Technology
Session at the SAGES Annual Meeting in Salt Lake City, Utah.
"We continue to receive feedback that the recent availability of the
MicroCutter XCHANGE 30 in the United States is enabling less invasive
gastrointestinal procedures with its small size and its ability to move 80
degrees in each direction," said Bernard A. Hausen, M.D., Ph.D., president and
CEO of Cardica. "Surgeons have been waiting for this functionality to advance
their less invasive surgical practice, and we are excited that this SAGES
presentation by Dr. Pescarus and colleagues demonstrates the potential shift
in patient care enabled by the MicroCutter."
Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to reduce operating time and facilitate
minimally-invasive and robot-assisted surgeries. Cardica's MicroCutter
XCHANGE^® 30, a cartridge-based articulating surgical stapling device with a
five-millimeter shaft diameter, is manufactured and cleared for use in a
variety of gastrointestinal procedures and appendectomies in the United
States, and is marketed for a wide range of surgical procedures in Europe.
Cardicais developing the Cardica^® MicroCutter XCHANGE^® 45, a
cartridge-based microcutter device with an eight-millimeter shaft to be used
in a variety of procedures, including bariatric, colorectal, thoracic and
general surgery. The Cardica MicroCutter XCHANGE 45 product requires 510(k)
review and CE Mark and is not yet commercially available in the U.S. or
internationally. In addition, Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 49,000 units throughout the world.
The statements in this press release regarding the benefits expected for
patients from Cardica's MicroCutter XCHANGE 30 and cartridges are
"forward-looking statements." There are a number of important factors that
could cause Cardica's results to differ materially from those indicated by
this forward-looking statement, including: that Cardica may not be successful
in its efforts to commercialize the XCHANGE 30 due to unanticipated technical
or other difficulties; that prospective customers in the United States may not
perceive the benefits of the XCHANGE 30 to be sufficient to warrant its
purchase; that prospective customers in the United States may be constrained
by pricing pressures or purchasing requirements in the hospitals and
facilities in which they work, which could prevent them from purchasing the
XCHANGE 30; as well as other risks detailed from time to time in Cardica's
reports filed with the U.S. Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter endedDecember 31, 2013, under
the caption "Risk Factors," filed on February 5, 2014. Cardica expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein. You are
encouraged to read Cardica's reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.
SOURCE Cardica, Inc.
Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
(650) 331-7133, email@example.com
Press spacebar to pause and continue. Press esc to stop.